Drug Type Synthetic peptide |
Synonyms |
Mechanism Bacterial outer membrane proteins inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Omnix Medical Ltd.Startup |
Active Organization Omnix Medical Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Qualified Infectious Disease Product (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hospital acquired bacterial pneumonia | Phase 2 | IL | Omnix Medical Ltd.Startup | 09 Oct 2024 |
VABP | Phase 2 | IL | Omnix Medical Ltd.Startup | 09 Oct 2024 |
Gram-Negative Bacterial Infections | Preclinical | US | Omnix Medical Ltd.Startup | 29 Dec 2018 |
Phase 2 | - | (idsgpnsxqr) = Upon single infusions, the half-life increases from 0.08h at 7.5 mg to about 0.9h at 80 and 100 mg. kqdyvbwjjy (yqclgehpsg ) View more | Positive | 10 May 2024 |